Skip to main content
Erschienen in: Clinical Rheumatology 12/2021

20.07.2021 | Original Article

IgA rheumatoid factor is associated with bone mineral density preservation in rheumatoid arthritis

verfasst von: Rim Sghiri, Asma Boumiza, Hana Benhassine, Nejla Elamri, Zahid Shakoor, Foued Slama, Adel Almogren, Imed Harrabi, Jihen Sahli, Latifa Guaddah, Hala Zeglaoui, Elyes Bouajina

Erschienen in: Clinical Rheumatology | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Autoantibodies such as IgM rheumatoid factor (RF) and anti-citrullinated proteins/peptides antibodies (ACPA) have previously been incriminated in systemic bone loss in rheumatoid arthritis (RA). There are, however, no data describing association of IgA RF and IgG RF with systemic bone loss.

Objective

This study was aimed to investigate the association of RF isotypes with systemic bone loss among patients with RA.

Methods

RF isotypes and ACPA were measured by enzyme-linked immunosorbent assay among 153 patients with RA. Bone mineral density (BMD) was assessed using dual-energy X-ray absorptiometry.

Results

Ninety-four (61.4%) patients had positive IgA RF, 89 (58.2%) had positive IgG RF, 109 (71.2%) had positive IgM RF, whereas 122 (80.3%) RA patients tested positive for ACPA. Compared to the IgA RF-negative patients, IgA RF-positive patients exhibited higher disease activity and had higher RF titers.
Seven (4.6%) patients had low BMD at femoral neck, 12 (7.8%) at total femur, and 47 (30.7%) at lumbar spine. IgA RF was found to be associated with protection against low BMD at spine (OR = 0.47, 95% CI = 0.23–0.95, p = 0.034). This association was further confirmed in the multivariate regression analysis taking into account several potential confounding factors (OR = 0.21, 95% CI = 0.06–0.65, p = 0.039). No association between low BMD and the presence of IgG RF or IgM RF or ACPA was found.

Conclusion

IgA RF for the first time ever was shown to be associated with BMD preservation at spine in RA.
Key points
IgA RF was associated with protection against low spinal BMD.
No association between low BMD and the presence of IgG RF or IgM RF was found.
Literatur
1.
Zurück zum Zitat Aletaha D, Neogi T, Silman AJ et al (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 62:2569–2581CrossRef Aletaha D, Neogi T, Silman AJ et al (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 62:2569–2581CrossRef
2.
Zurück zum Zitat Tarkowski A, Nilsson LA (1983) Isotype-specific measurement of rheumatoid factor with reference to clinical features of rheumatoid arthritis. J Clin Lab Immunol 12:129–135PubMed Tarkowski A, Nilsson LA (1983) Isotype-specific measurement of rheumatoid factor with reference to clinical features of rheumatoid arthritis. J Clin Lab Immunol 12:129–135PubMed
3.
Zurück zum Zitat Silvestris F, Goodwin JS, Williams RC Jr (1985) IgM, IgA and IgG rheumatoid factors in patients with rheumatoid arthritis and normal donors. Clin Rheumatol 4:392–398CrossRef Silvestris F, Goodwin JS, Williams RC Jr (1985) IgM, IgA and IgG rheumatoid factors in patients with rheumatoid arthritis and normal donors. Clin Rheumatol 4:392–398CrossRef
4.
Zurück zum Zitat Allen C, Elson CJ, Scott DG et al (1981) IgG antiglobulins in rheumatoid arthritis and other arthritides: relationship with clinical features and other parameters. Ann Rheum Dis 40:127–131CrossRef Allen C, Elson CJ, Scott DG et al (1981) IgG antiglobulins in rheumatoid arthritis and other arthritides: relationship with clinical features and other parameters. Ann Rheum Dis 40:127–131CrossRef
5.
Zurück zum Zitat Jonsson T, Valdimarsson H (1993) Is measurement of rheumatoid factor iso-types clinically useful? Ann Rheum Dis 52:161–164CrossRef Jonsson T, Valdimarsson H (1993) Is measurement of rheumatoid factor iso-types clinically useful? Ann Rheum Dis 52:161–164CrossRef
8.
Zurück zum Zitat Klareskog L, Stolt P, Lundberg K et al (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54:38–46CrossRef Klareskog L, Stolt P, Lundberg K et al (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54:38–46CrossRef
9.
Zurück zum Zitat Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA et al (2006) Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 65:366–371CrossRef Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA et al (2006) Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 65:366–371CrossRef
10.
Zurück zum Zitat Chatzidionysiou K, Lie E, Nasonov E et al (2011) Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum 70:1575–1580CrossRef Chatzidionysiou K, Lie E, Nasonov E et al (2011) Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum 70:1575–1580CrossRef
11.
Zurück zum Zitat Gottenberg JE, Courvoisier DS, Hernandez MV et al (2016) Rheumatoid factor and anti-citrullinated protein antibody positivity are associated with a better effectiveness of abatacept: results from the Pan-European registry analysis. Arthritis Rheumatol 68:1346–1352CrossRef Gottenberg JE, Courvoisier DS, Hernandez MV et al (2016) Rheumatoid factor and anti-citrullinated protein antibody positivity are associated with a better effectiveness of abatacept: results from the Pan-European registry analysis. Arthritis Rheumatol 68:1346–1352CrossRef
12.
Zurück zum Zitat Arnason JA, Jónsson T, Brekkan A et al (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095CrossRef Arnason JA, Jónsson T, Brekkan A et al (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095CrossRef
13.
Zurück zum Zitat Árnason JA, Jónsson T, Brekkan Á et al (1987) Relation between bone erosions and rheumatoid factor isotypes. Ann Rheum Dis 46:380–384CrossRef Árnason JA, Jónsson T, Brekkan Á et al (1987) Relation between bone erosions and rheumatoid factor isotypes. Ann Rheum Dis 46:380–384CrossRef
14.
Zurück zum Zitat Takayanagi H (2009) Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 5:667–676CrossRef Takayanagi H (2009) Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 5:667–676CrossRef
15.
Zurück zum Zitat Ritchlin CT, Haas-Smith SA, Li P et al (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111:821–831CrossRef Ritchlin CT, Haas-Smith SA, Li P et al (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111:821–831CrossRef
16.
Zurück zum Zitat Geusens P (2012) The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis 4:225–233CrossRef Geusens P (2012) The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis 4:225–233CrossRef
17.
Zurück zum Zitat Kleyer A, Finzel S, Rech J et al (2014) Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 73:854–860CrossRef Kleyer A, Finzel S, Rech J et al (2014) Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 73:854–860CrossRef
18.
Zurück zum Zitat Harre U, Kittan NA, Schett G (2014) Autoantibody-mediated bone loss. Curr Osteoporos Rep 12:17–21CrossRef Harre U, Kittan NA, Schett G (2014) Autoantibody-mediated bone loss. Curr Osteoporos Rep 12:17–21CrossRef
19.
Zurück zum Zitat Harre U, Georgess D, Bang H et al (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791–1802CrossRef Harre U, Georgess D, Bang H et al (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791–1802CrossRef
20.
Zurück zum Zitat Orsolini G, Caimmi C, Viapiana O et al (2017) Titer-Dependent effect of anti-citrullinated protein antibodies On systemic bone mass in rheumatoid arthritis patients. Calcif Tissue Int 101:17–23CrossRef Orsolini G, Caimmi C, Viapiana O et al (2017) Titer-Dependent effect of anti-citrullinated protein antibodies On systemic bone mass in rheumatoid arthritis patients. Calcif Tissue Int 101:17–23CrossRef
21.
Zurück zum Zitat Llorente I, Merino L, Ortiz AM et al (2017) Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients. Rheumatol Int 37:799–806CrossRef Llorente I, Merino L, Ortiz AM et al (2017) Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients. Rheumatol Int 37:799–806CrossRef
22.
23.
Zurück zum Zitat Sharp JT, Wolfe F, Mitchell DM et al (1991) The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 34:660-668SCrossRef Sharp JT, Wolfe F, Mitchell DM et al (1991) The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 34:660-668SCrossRef
24.
Zurück zum Zitat Sghiri R, Bouajina E, Bargaoui D et al (2008) Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis. Rheumatol Int 29:59–62CrossRef Sghiri R, Bouajina E, Bargaoui D et al (2008) Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis. Rheumatol Int 29:59–62CrossRef
25.
Zurück zum Zitat Sghiri R, Bouagina E, Zaglaoui H et al (2007) Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Rheumatol Int 27:1125–1130CrossRef Sghiri R, Bouagina E, Zaglaoui H et al (2007) Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Rheumatol Int 27:1125–1130CrossRef
26.
Zurück zum Zitat Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group Osteoporos Int 4:368–381CrossRef Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group Osteoporos Int 4:368–381CrossRef
27.
Zurück zum Zitat Aho K, Heliövaara M, Maatela J et al (1991) Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 18:1282–1284PubMed Aho K, Heliövaara M, Maatela J et al (1991) Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 18:1282–1284PubMed
28.
Zurück zum Zitat Rantapää-Dahlqvist S, de Jong BA, Berglin E et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749CrossRef Rantapää-Dahlqvist S, de Jong BA, Berglin E et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749CrossRef
29.
Zurück zum Zitat Teitsson I, Withrington RH, Seifert MH et al (1984) Prospective study of early arthritis. I. Prognostic value of IgA rheumatoid factor. Ann Rheum Dis 43:673–678CrossRef Teitsson I, Withrington RH, Seifert MH et al (1984) Prospective study of early arthritis. I. Prognostic value of IgA rheumatoid factor. Ann Rheum Dis 43:673–678CrossRef
30.
Zurück zum Zitat Lúthvíksson BR, Jónsson T, Erlendsson K et al (1992) Disease manifestations in patients with isolated elevation of IgA rheumatopid factor. Scand J Rheumatol 21:1–4CrossRef Lúthvíksson BR, Jónsson T, Erlendsson K et al (1992) Disease manifestations in patients with isolated elevation of IgA rheumatopid factor. Scand J Rheumatol 21:1–4CrossRef
31.
Zurück zum Zitat Eberhardt KB, Svensson B, Truedsson L et al (1988) The occurrence of rheumatoid factor isotypes in early definite rheumatoid arthritis. J Rheumatol 15:1070–1074PubMed Eberhardt KB, Svensson B, Truedsson L et al (1988) The occurrence of rheumatoid factor isotypes in early definite rheumatoid arthritis. J Rheumatol 15:1070–1074PubMed
32.
Zurück zum Zitat Gioud-Paquet M, Auvinet M, Raffin T et al (1987) IgM rheumatoid factor (RF), IgA RF, IgE RF, and IgG RF detected by ELISA in rheumatoid arthritis. Ann Rheum Dis 46:65–71CrossRef Gioud-Paquet M, Auvinet M, Raffin T et al (1987) IgM rheumatoid factor (RF), IgA RF, IgE RF, and IgG RF detected by ELISA in rheumatoid arthritis. Ann Rheum Dis 46:65–71CrossRef
33.
Zurück zum Zitat Russell MW, Sibley DA, Nikolova EB et al (1997) IgA antibody as a non-inflammatory regulator of immunity. Biochem Soc Trans 25:466–470CrossRef Russell MW, Sibley DA, Nikolova EB et al (1997) IgA antibody as a non-inflammatory regulator of immunity. Biochem Soc Trans 25:466–470CrossRef
34.
Zurück zum Zitat Schaffer FM, Monteiro RC, Volanakis JE et al (1991) IgA deficiency. Immunodefic Rev 3:15–44PubMed Schaffer FM, Monteiro RC, Volanakis JE et al (1991) IgA deficiency. Immunodefic Rev 3:15–44PubMed
35.
Zurück zum Zitat Rossato E, Ben Mkaddem S, Kanamaru Y et al (2015) Reversal of arthritis by human monomeric IgA through the receptor-mediated SH2 domain-containing phosphatase 1 inhibitory pathway. Arthritis Rheumatol 67:1766–1777CrossRef Rossato E, Ben Mkaddem S, Kanamaru Y et al (2015) Reversal of arthritis by human monomeric IgA through the receptor-mediated SH2 domain-containing phosphatase 1 inhibitory pathway. Arthritis Rheumatol 67:1766–1777CrossRef
36.
Zurück zum Zitat Ben Mkaddem S, Rossato E, Heming N (2013) Anti-inflammatory role of the IgA Fc receptor (CD89): from autoimmunity to therapeutic perspectives. Autoimmun Rev 12:666–669CrossRef Ben Mkaddem S, Rossato E, Heming N (2013) Anti-inflammatory role of the IgA Fc receptor (CD89): from autoimmunity to therapeutic perspectives. Autoimmun Rev 12:666–669CrossRef
37.
Zurück zum Zitat MacLellan LM, Montgomery J, Sugiyama F et al (2011) Co-opting endogenous immunoglobulin for the regulation of inflammation and osteoclastogenesis in humans and mice. Arthritis Rheum 63:3897–3907CrossRef MacLellan LM, Montgomery J, Sugiyama F et al (2011) Co-opting endogenous immunoglobulin for the regulation of inflammation and osteoclastogenesis in humans and mice. Arthritis Rheum 63:3897–3907CrossRef
38.
Zurück zum Zitat Delamere JP, Farr M, Grindulis KA (1983) Sulphasalazine induced selective IgA deficiency in rheumatoid arthritis. Br Med J (Clin Res Ed) 286:1547–1548CrossRef Delamere JP, Farr M, Grindulis KA (1983) Sulphasalazine induced selective IgA deficiency in rheumatoid arthritis. Br Med J (Clin Res Ed) 286:1547–1548CrossRef
39.
Zurück zum Zitat Bugatti S, Bogliolo L, Vitolo B et al (2016) arthritis. Arthritis Res Ther 18:226CrossRef Bugatti S, Bogliolo L, Vitolo B et al (2016) arthritis. Arthritis Res Ther 18:226CrossRef
40.
Zurück zum Zitat Onal M, Xiong J, Chen X et al (2012) Receptor activator of nuclear factor kB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem 287:29851–29860CrossRef Onal M, Xiong J, Chen X et al (2012) Receptor activator of nuclear factor kB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem 287:29851–29860CrossRef
41.
Zurück zum Zitat Zhu LJ, Dai L, Zheng DH et al (2012) Upregulation of tumor necrosis factor receptor associated factor 6 correlated with synovitis severity in rheumatoid arthritis. Arthritis Res Ther 14:R133CrossRef Zhu LJ, Dai L, Zheng DH et al (2012) Upregulation of tumor necrosis factor receptor associated factor 6 correlated with synovitis severity in rheumatoid arthritis. Arthritis Res Ther 14:R133CrossRef
42.
Zurück zum Zitat Hassine HB, Zemni R, Nacef IB et al (2019) A TRAF6 genetic variant is associated with low bone mineral density in rheumatoid arthritis. Clin Rheumatol 38:1067–1074CrossRef Hassine HB, Zemni R, Nacef IB et al (2019) A TRAF6 genetic variant is associated with low bone mineral density in rheumatoid arthritis. Clin Rheumatol 38:1067–1074CrossRef
Metadaten
Titel
IgA rheumatoid factor is associated with bone mineral density preservation in rheumatoid arthritis
verfasst von
Rim Sghiri
Asma Boumiza
Hana Benhassine
Nejla Elamri
Zahid Shakoor
Foued Slama
Adel Almogren
Imed Harrabi
Jihen Sahli
Latifa Guaddah
Hala Zeglaoui
Elyes Bouajina
Publikationsdatum
20.07.2021
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 12/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-021-05814-4

Weitere Artikel der Ausgabe 12/2021

Clinical Rheumatology 12/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.